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Functional Evaluation of Lipid-Lowering 
Therapy by Pravastatin in the Regression 
Growth Evaluation Statin Study (REGRESS)
Wim R.M. Aengevaeren, MD; Gerard J.H. Uijen, PhD; J. Wouter Jukema, MD;
Albert V.G. Bruschke, MD; Tjeerd van der Werf, MD
Background Lipid-lowering therapy during 2 years in the 
Regression Growth Evaluation Statin Study (REGRESS) was 
associated with less progression of coronary atherosclerosis in 
the pravastatin group compared with the placebo group. The 
effect of lipid-lowering therapy on the functional state of the 
coronary circulation is less well known. The purpose of this 
study was to evaluate this effect.
Methods and Results In a substudy of REGRESS, 69 pa­
tients were randomized to pravastatin or placebo. Thirty-seven 
of these patients were allocated to the medical management 
stratum. Quantitative coronary angiography, regional myocar­
dial perfusion, exercise testing, and classification of angina 
pectoris were assessed at baseline and after 2 years of therapy. 
Regional myocardial perfusion was assessed by digital subtrac­
tion angiography after intracoronary papaverine with video- 
densitometric calculation of the hyperemic mean transit time 
(HMTT) of contrast. In the medical management stratum, 
regional myocardial perfusion was assessed in 31 regions in the 
pravastatin group and 25 regions in the placebo group. The
In the multifactorial pathogenesis of coronary ath­erosclerosis, an elevated cholesterol level is a causal factor.1 Numerous studies have shown that in patients with coronary artery disease, HMG-coen- 
zyme A  reductase inhibitors have a beneficial effect on 
the incidence of cardiovascular events and development 
of coronary atherosclerosis.2"7 In several angiographic 
trials, the reduction of clinical events was more pro­
nounced than would be expected by the modest influ­
ence of lipid lowering on progression of atherosclerosis, 
which suggests the possibility of a plaque stabilizing 
effect.7»8 In normal coronary arteries, the endothelium 
produces endothelium-derived relaxing factor, which 
protects the vessel wall by inhibiting platelet adhesion 
and aggregation, smooth muscle cell proliferation, and 
smooth muscle cell contraction. Atherosclerosis and 
hypercholesterolemia have a detrimental effect on endo-
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change in HMTT in the pravastatin group was —0.18 seconds 
(-5%) and in the placebo group +0.52 seconds (+18%), a 
difference of 0.70 seconds (P^.004). The m e a n  difference in 
change in classification of angina pectoris (scale, 1 to 4) 
between pravastatin and placebo was 0.7 (P = .0 3 )  in favor of 
the pravastatin-treated patients. The change in H M TT was 
correlated with the change in exercise time ( r=  — .65, P=.002).
Conclusions In patients with symptomatic coronary artery 
disease, treatment with the HMG-co enzyme A  reductase in­
hibitor pravastatin during 2 years resulted in a  preserved 
regional myocardial perfusion, whereas patients  on placebo 
deteriorated. The classification of angina pectoris  improved 
only in patients receiving pravastatin. In lipid-lowering therapy, 
the evaluation of myocardial perfusion by assessment of the 
HMTT reveals a combined measure of functional and struc­
tural changes in the coronary circulation. (Circulation. 
1997;96:429-435.)
Key Words •  perfusion • exercise •  co ronary  disease • 
angiography • lipids
thelial function in both the epicardial coronary arteries 
and the resistance vessels.9-11 Exercise induces a meta­
bolic vasodilatation in the resistance vessels and a flow- 
mediated dilatation of the epicardial vessels, which is 
endothelium dependent.12 Endothelial dysfunction leads 
to paradoxical vasoconstriction with impairment of myo­
cardial perfusion and contributes to the pathogenesis of 
myocardial ischemia. Cholesterol lowering may restore 
the endothelial function.13'15 Translated to the clinical 
situation, lipid-lowering therapy should have a beneficial 
effect on maximal myocardial perfusion and the occur­
rence of myocardial ischemia. The impact of lipid- 
lowering drugs on functional parameters such as myo­
cardial perfusion, exerciserinduced ischem ia, and 
anginal complaints in patients with coronary atheroscle­
rosis is not well known. In this study, we evaluated the 
functional effect of pravastatin therapy and compared 
the results with the anatomic evaluation by QCA in 
symptomatic patients with normal to moderately ele­
vated cholesterol.
Methods
REGRESS is a double-blind, placebo-controlled, multi­
center study designed to assess the effect o f  2  years of treat­
ment with the HMG-coenzyme A  reductase inhibitor  pravasta­
tin on progression and regression of  angiographica l ly  
documented coronary atherosclerosis in male patients  with a 
cholesterol level between 4 and 8 mmol/L (155 a n d  310 mg/dL). 
Patients participating in this study were rec ru i ted  from the 
waiting list of patients scheduled to undergo coronary  angiog-
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Selected Abbreviations and Acronyms
CABG ~  coronary artery bypass graft surgery 
H M T T  =  hyperemic mean transit time 
M O D  =  minimal obstruction diam eter 
MSD =  m ean segment d iam eter 
PTCA = percutaneous transluminal coronary
angioplasty 
Q CA  = quantitative coronary angiography 
R EG R ESS -  Regression Growth Evaluation Statin Study
raphy. Patients who were included at the University Hospital 
Nijmegen underwent, in addition to the REGRESS protocol, 
assessment of regional myocardial perfusion for functional 
evaluation of the effect of pravastatin. The study was approved 
by the ethics committee of the University Hospital Nijmegen, 
and written informed consent was obtained from all patients. In 
short, included were 18- to 70-year-old male patients with 
proven coronary artery disease (at least one coronary diameter 
stenosis s50%). The study design, definition of clinical events, 
and methods assessment of lipid levels and QCA have been 
reported previously.7 After cardiac catheterization, patients 
were stratified in three strata—medical management, PTCA, 
or CABG—and subsequently randomized to pravastatin 40 mg 
once daily or placebo. Because bypass grafts and PTCA may 
have a major impact on flow, distribution of flow, and exercise 
results, patients who underwent these procedures were ex­
cluded from functional evaluation of the effect of pravastatin, 
QCA was evaluated by assessment of MOD and MSD on the 
basis of per-patient and per-segment measurements.
Assessment of Myocardial Perfusion
Myocardial perfusion was assessed by digital subtraction 
angiography with videodensitometric calculation of the HMTT 
of contrast passage through the capillary bed. This method has 
been developed in our laboratory in accordance with the 
principles of the indicator dilution theory and has been vali­
dated in model studies, animal experiments, and humans.16'18 
The short-term reproducibility of the method has been evalu­
ated with a relative difference of 5 ± 5 %  for repeated measure­
ments with a correlation coefficient of .97.18 To exclude auto- 
regulatory changes in the coronary circulation and to ensure a 
constant and maximal vascular volume, the assessment of 
myocardial perfusion was performed during maximal hyper­
emia induced by papaverine. The derived time parameter, 
HMTT, is inversely related to myocardial perfusion. We used 
this method to compare the maximal regional myocardial 
perfusion in the areas of the left anterior descending artery, 
right circumflex artery, and right coronary artery at baseline 
and at follow-up. The methods of image acquisition, analysis of 
the time-density curves, and correction of the HMTT to a mean 
aortic blood pressure of 100 mm Hg and the final calculations 
of the regional HMTTs have been described previously.19 
Calculation of the HMTTs was performed with blinding to 
treatment allocation. Effect analysis of the lipid-lowering treat­
ment was based primarily on the regional change in myocardial 
perfusion. The patient-based evaluation was performed by 
averaging the regional HMTT values to one value per patient 
as a global estimate of myocardial perfusion.
Exercise Testing
Exercise testing was performed at baseline and at follow up 
after 2 years. Antianginal medication was not discontinued. An 
electronically braked bicycle ergometer (Marquette Case 15, 
Marquette Electronics Inc) was used, along with continuous 
ECG monitoring. The exercise was started at a load of 50 W, 
followed by a 10-W increase every minute until maximal 
exercise was achieved, chest discomfort occurred, or usual 
criteria for stopping a test were applied. Blood pressure was 
recorded every 2 minutes, directly after maximal exercise, and
T a b l e  1. Baseline Characteristics
Pravastatin
(n=35)
Placebo
(n=34) P*
Age, y 56.5±8.0 55.0±7.8 .43
Length, m 173±6 176±7 .03
Weight, kg 80.1 ±11.1 82.9±11.0 .33
Blood pressure, mm Hg
Systolic 135±22 137+16 .65
Diastolic 77±8 80±10 .20
Previous myocardial infarction, n 20 21 .70
History of hypertension, n 4 8 .19
Diabetes mellitus, n 0 0 1.0
Angina pectoris classificationt 2.5±0.7 2.4±1.0 .72
Ejection fraction angiographic 0.66±0.13 0.66±0.16 .94
Drug treatment
j3-Blockers 26 27 .69
Calcium channel blockers 14 16 .87
Long-acting nitrates 21 13 .12
Values are mean±SD when appropriate.
*One~way AN OVA or the Kruskal-Wallis test as appropriate. 
tAccording to the Canadian Cardiovascular Society at the Intake visit.
at rest in the second and fifth minute. Automated calculation 
was performed of ST-segment depression 80 ms beyond the 
J-point Variables used for analysis included maximal work­
load, time until the onset of 0.1-mV (1-mm) horizontal or 
downsloping ST-segment depression, maximal ST-segment de­
pression, and maximal rate-pressure product. The patients who 
underwent nonscheduled interventions in the medical manage­
ment stratum were excluded from the effect analysis. Patients 
with an abnormal ECG at the baseline exercise test were also 
excluded from analysis.
Classification of Angina Pectoris
After randomization at the first visit and at follow-up after 2 
years, angina pectoris was classified in all patients according to 
the Canadian Cardiovascular Society.20 The data were analyzed 
in two ways: first, for the whole group, regardless of nonsched­
uled interventions; second, in the medical management stra­
tum. However, the moment of classification of the angina 
pectoris was taken before any nonscheduled intervention.
Statistical Analysis
Comparison of prespecified continuous variables was per­
formed within the groups by two-sided paired t tests; between- 
group analysis was performed by unpaired t tests and one-way 
ANOVA. For categorical comparisons, a x 2 test or the 
Kruskal-Wallis test was performed when appropriate. Correla­
tions were tested with Pearson’s correlation coefficient. Regres­
sion analysis was used to compare the change in HMTT with 
change in exercise parameters and change in QCA data. 
Calculations were performed on a personal computer with the 
statistical package SPSS for Windows (releases 6.1 and 7.0). A 
two-sided value of P< . 05 was considered significant. Results 
were expressed as mean±SD unless otherwise indicated.
Results
Sixty-nine patients were included; subsequently, 35 
patients were randomized to the pravastatin group and 
34 patients to the placebo group. The groups were well 
matched for demographic variables (Table 1). The final 
distribution of the study group in the three treatment 
strata resulted in 37 patients in the medical management 
stratum (pravastatin, n=19; placebo, n=18), 16 patients 
in the PTCA stratum, and 16 patients in the CABG 
stratum. Fifty-seven patients completed the study ac­
cording to the protocol: 32 patients in the medical 
management stratum, 11 in the PTCA stratum, and 14 in
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T able 2. Mean Lipoprotein Levels Before and During Treatment in the Placebo and Pravastatin Groups
Pravastatin (n=35) Placebo (n=34)
Placebo vs 
PravastatinBaseline
During
Treatment
Difference,
% Baseline
During
Treatment
Difference,
%
Total cholesterol, mmot/L 6.15±0.80 5.09±0.74 -1 7 * 6.20±1.01 6.26±0.86 + 1 <0.001
LDL cholesterol, mmoI/L 4.30±0.74 3.29+0.70 -23* 4.38+0.92 4.43+0,81 +1 <0.001
HDL cholesterol, mmol/L 0.89±0.24 0.95±0.19 +7* 0.94+0.24 0.94+0.19 0 0,09
Triglycerides, mmol/L 2.13±0.86 1.90+0.87 -1 1 * 1.95+0.67 1.96+0.64 + 1 0.05
Values are mean±SD when appropriate. 
*P<. 05.
the CABG stratum. Dropouts were due to refusal of the 
second cardiac catheterization in 7 patients, death in 3 
patients (two sudden deaths— one in the medical man­
agement stratum and one in the PTCA stratum—and 
one death in the CABG stratum in a patient who died 
shortly after CABG because of heart failure), and 
noncardiac causes in 2 patients. In the medical manage­
ment stratum, 6 nonscheduled interventions were car­
ried out: 1 PTCA in the pravastatin group and 4 PTCAs 
and 1 CABG in the placebo group. Table 2 gives the 
mean lipid levels at baseline and during the study. Table
3 shows the QCA data of the medical management 
stratum. During the study, there was no important 
change in antianginal medication.
Myocardial Perfusion
In the medical management stratum group, compar­
ative baseline and follow-up digital subtraction angiog­
raphies were available in 25 patients. Table 4 gives the 
results of the region-based HMTT assessment in the 
perfusion areas of the left anterior descending coronary 
artery, right circumflex artery, and right coronary artery. 
The baseline value of regional HMTT in the pravastatin 
group was 3.36±1.03 versus 2.92±0.75 seconds in the 
placebo group (P=.08). In the per-patient evaluation, 
the HMTT in the pravastatin group (n=15) changed 
from 3.33±0.81 to 3.23±0.60 seconds, a difference of 
—0.10 seconds (—3%; 75). In the placebo group 
(n=10), the per-patient HMTT changed from 2.91±0.33 
to 3.39±0.59 seconds, a difference of +0.48 seconds 
(+16%; P=.01). The difference in change between the 
pravastatin and placebo groups was 0.58 seconds 
(P=.045). The baseline values of the pravastatin and 
placebo groups on a per-patient base were not signifi­
cantly different (P=.14).
In the PTCA stratum group, 11 patients had follow-up 
cardiac catheterization. PTCA was performed in 12 
vessels in these 11 patients. In 1 vessel, repeated PTCA
was performed. Baseline and follow-up regional HMTT 
values were available in 9 regions of the P T C A  vessels 
and 15 regions of the nonintervention vesse ls . Table 5 
shows the results of regional HMTT in  the PTCA 
stratum.
Exercise Testing
In the medical management stratum, 24 o f  35 patients 
had a follow-up exercise test without intercurrent PTCA 
or CABG. If patients had a nonscheduled PTCA or 
CABG in the medical management stratum, most often 
this occurred after a period of progressive or unstable 
angina pectoris, and in this setting, no exercise tests were 
performed. Table 6 gives the effect analysis of the 
exercise testing in the medical management stratum. 
Baseline exercise tests were positive (1-ram horizontal or 
downsloping ST-segment depression) in o n ly  11 of 30 
tests (37%): 6 in the pravastatin group and 5 in the 
placebo group. At follow-up, exercise tests w ere  positive 
in 4 patients in the pravastatin group and 3 patients in 
the placebo group.
In the PTCA and CABG strata, baseline exercise tests 
were judged as positive in 18 of 29 tests (62%). At 
follow-up, 12 of 24 available tests converted to negative. 
None of the negative tests changed to positive. In these 
strata, no change in exercise response ex isted  between 
pravastatin and placebo.
Classification of Angina Pectoris
In the medical management stratum, the angina pec­
toris classifications (at a scale of 1 to 4) fo r  the prava­
statin and placebo groups at baseline were 2/1 ±0.5 and 
1.8±0.8; at follow-up, they were 1.4±1.0 and 1.7±1.0, 
respectively. In 3 patients in the placebo group and 1 
patient in the pravastatin group, follow -up was not 
available. The mean difference in change o f angina 
pectoris classification between pravastatin and placebo 
was 0.7 (?=.03; Fig 1).
Table 3. Results of QCA in the Medical Management Stratum
Pravastatin Placebo
--------------------------------- -------- ---------------  —-------------------------------------------------------  Treatment
n Baseline Follow-up Difference n Baseline Follow-up Difference E ffect P
Pre-patient 17 14
measurement, mm
MSD 2.99+0.44 2.97+0.41 -0 .02  2.83+0.40 2.83±0.39 0.00 - 0 . 0 2  NS
MOD 2.05±0.35 1.97±0.43 -0 .08  1.87+0.37 1.77±0.42 -0 .1 0 * O .02 NS
Per-segment 152 118
measurement, mm
MSD 2.99±0.94 2.97±0.89 -0 .02  2.85+0.99 2.84±1.02 -0 .01  - 0 .0 1  NS
MOD 2.08±0.87 2.04+0.88 -0 .04  1.90+0.81 1.79+0.85 -0 .11 * O .07 NS
Values are mean+SD when appropriate. 
*P<.05.
432 Circulation Vol 96, No 2 July 15, 1997
T able  4. Régional HMTT Values in thè Medicai Management Group
LAD Region RCx Region RCA Region All Regions
Pravastatin, n 12 9 10 31
Baseline HMTT, s 2.89±0.87 3.11 ±0.94 4.14±0.88 3.36+1.03
Follow-up HMTT, s 2.97±0.59 2.95+0,42 3.65+1.10 3.18+0.86
P .76 .57 .12 .27
Placebo 10 9 6 25
Baseline HMTT, s 2.84±0.78 2.46±0.44 3.75±0.29 2.92±0.75
Fo|[ow~up HMTT, s 3.05±0.44 3.13±0.77 4.56±1.38 3.44±1.04
P .37 .03 .16 .006
Difference, P* .71 .04 ,03 .004
Values are mean±SD when appropriate. LAD indicates left anterior descending artery; 
RCx, right circumflex artery; RCA, right coronary artery.
^Difference in mean change between pravastatin and placebo groups (t test).
In the combined PTCA and CABG stratum (n=32), 
the baseline classification of angina pectoris was 
3.1 ±0.6, whereas in the medical management stratum 
(n ^ ^ ), the baseline classification was 1.9±0.7 (a differ­
ence of 1,2, Pc.001). At follow-up, the classification of 
angina pectoris was 1.6±0.8 for the medical manage­
ment stratum and 1.3±0.5 for the combination of PTCA 
and CABG strata (a difference of 0.3, P=.12). In the 
CABG and PTCA strata, angina pectoris reduced from 
baseline to follow-up in the pravastatin group with 
1,7±0.8 and in the placebo group with 1.9±0.9 (P=.52).
Clinical Events
Although this substudy was rather small, a remarkable 
number of clinical events could be registered. In the 
placebo group, 13 of 34 patients had a total of 15 clinical 
events versus 7 clinical events in 5 of 35 patients in the 
pravastatin group (x2, 3.96; PC.05, with Yates’ correc­
tion). The clinical events were the main reason for loss 
of follow-up in the medical management stratum.
Correlations and Regression Analysis in the 
Medical Management Stratum
The change in MSD was correlated with the change in 
MOD (n=31, r=,62, Pc.001) but not with the change in 
exercise parameters (n—24) or HMTT (n=25). The 
change in MOD was correlated with the change in 
ST-segment depression (n=24, r= —.52, P=.009). The 
change in percentage stenosis was also correlated with 
the change in ST-segment depression (n=24, r=.41, 
P=.046) and with the time to 1-mm ST-segment depres­
sion (n=6, r= ,89, P=.017). The change in HMTT was 
correlated with the change in exercise time (n=20, 
/*=—.65, P=.002; see Fig 2) and with the maximal load 
(n=20, r= —.47, P=.037) but not with the other exercise 
parameters. In the stepwise multiple regression, the 
change in HMTT was explained by the combination of 
changes in total exercise time and MOD (n=19, multiple 
r=.76, P^O.0007). The parameters included in this step­
wise multiple regression were change in exercise time,
change in MOD, change in MSD, and change in LDL 
level.
Discussion
The results of this study show that in patients with 
coronary artery disease and a cholesterol level between
4 and 8 mmol/L, pravastatin had a favorable effect on 
regional myocardial perfusion compared with placebo. 
In the pravastatin group, there was a slight increase in 
regional myocardial perfusion in the absence of artério­
graphie evidence of regression, The results of the exer­
cise tests and classification of angina pectoris, however, 
were concordant with the assessment of regional myo­
cardial perfusion. The discrepancy between the im­
proved myocardial perfusion and the progression of 
coronary artery disease in the pravastatin group might 
be explained by an improved endothelium-dependent 
relaxation.
Myocardial Perfusion
The baseline HMTT values in the placebo group were 
shorter than those in the pravastatin group, although the 
difference was not statistically significant. This phenom­
enon may be explained by the small sample size and 
more right coronary artery regions in the pravastatin 
than in the placebo group (13 versus 7, respectively). In 
general, HMTT values in the right coronary artery 
region are about 1 second longer, which is the mean time 
required for contrast passage from the ostium of the 
right coronary artery to the crux. Because interventions 
such as CABG and PTCA may also influence myocardial 
perfusion in remote noninterventional regions, these 
strata were excluded from effect analysis of pravastatin 
on myocardial perfusion.21»22 The results of the determi­
nation of myocardial perfusion were better related with 
exercise parameters than with anatomic parameters. The 
assessment of the relation of the change in QCA param­
eters and the change in HMTT is hampered by a few 
problems. The QCA analysis of progression and regres­
sion was a patient-based comparison, whereas changes
Table 5, Regional HMTT in the PTCA Stratum
Baseline HMTT Before 
Intervention, s
Follow-up HMTT 
After 2y, s
HMTT
Difference, s P
Intervention regions (n=9) 
Nonintervention regions (n -15)
4.19 ±  1.66 
3.07±0.56
3.16+1.01
2.87+0.88
-1 .03+0 .93  
—0.20±0.92
.01
.41
Nonintervention regions are the regional HMTTs of the PTCA stratum. Data of pravastatin and placebo 
groups are pooled for both the intervention and nonintervention regions. The difference in change between 
intervention and nonintervention regions was significant (P<.05).
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Table 6. Results of Exercise Testing in the Medical Management Stratum
Resting heart rate, bpm
Resting systolic blood pressure, mm Hg
Maximal heart rate, bpm
Maximal systolic blood pressure, mm Hg
Total exercise time, s
ST time, s
ST max, mm
Maximal heart rate-*systolic blood pressure 
product, mm Hg/minxlO-3
Maximal load, W
Pravastatin (n=14)
Baseline
73±14  
136±27 
128±28 
M l ±27 
649 ±  192 
399±224 
1.04±1.01 
22.9±6.8
145±34
After 2 y
66±12 
141 ±42 
126±29 
189±42 
632±116 
555±133 
0.72 ±1.07 
24.2±8.4
148±23
P*
.05
.42
.73
.26
.65
.58
.13
.41
.62
Placebo (n=10)
Baseline
62±13 
143±24 
138±25 
188±31 
758±241 
567±320 
0.65±0.75 
26.2 ±7.1
164±41
After 2 y
69±8  
129±14  
132±19  
184±36  
653±224  
397±410 
0.65±0.69  
24.5±6.8
155±37
P
.41
.23
.43
.7 5
.0 6
.31
1.0
,51
.22
Difference, 
f t
.06 
.32 
.65 
.11 
.17 
.21 
.34 
.12
.19
ST time indicates time to 1-mm ST-segment depression; ST max, maximum ST-segment depression. Values are mean±SD when appropriate . Bicycle 
exercise ECG at baseline and after 2 years of therapy.
‘Paired t test baseline vs 2 y.
tUnpaired t test of the differences between baseline and 2 y in the pravastatin and placebo groups.
in MOD may be restricted to one segment. The regional 
HMTT data were averaged to a mean value per patient 
on the basis of a mean of 1.6 perfusion areas per patient. 
The areas of regional HMTT do not necessarily corre­
spond with the vessel segments that were averaged for 
the per-patient QCA results. Finally, the expected rela­
tion of change in myocardial perfusion and coronary 
diameter is not linear.
Maximal myocardial perfusion is determined by the 
resistance in both the conductance vessels and the 
micro circulation. Because of the method of assessment 
of the HMTT (sublingual isosorbide dinitrate before the 
coronary angiography and intracoronary papaverine 
during the image acquisition), the hyperemia is induced 
by an endothelium-independent vasodilatation of the 
resistance vessels and a flow-mediated vasodilatation of 
the epicardial vessels. The flow-mediated response is 
endothelium dependent.23 The difference in myocardial 
perfusion between the pravastatin and placebo groups 
might be induced by an impaired flow-mediated vasodi­
latation in the epicardial vessels in response to the 
induced hyperemia in the resistance vessels in the pla­
cebo group. This hypothesis is adapted from Gould et 
al,24 who described this phenomenon in relation to 
dipyridamole infusion intravenously during PET for flow 
assessment in lipid-lowering therapy by diet. The admin­
istration of isosorbite dinitrate just before the coronary
angiogram might have blunted the endothelium-depen­
dent response. However, the difference in change 
between the pravastatin and placebo groups of regional 
myocardial reperfusion are remarkable.
Exercise Testing
Fixed atherosclerotic obstructions and endothelium- 
dependent relaxation of the resistance an d  epicardial 
vessels are determinants of exercise capacity and exer­
cise-induced ischemia. Although the number of patients 
studied was relatively small, the group o f  patients on 
pravastatin showed a trend toward less ischem ia, a lower 
heart rate at rest, and a better preserved exercise 
tolerance compared with the placebo group. These 
effects may be due in part to a preserved or improved 
endothelial function.
Classification of Angina Pectoris
As could be expected, baseline angina pectoris was 
worse in the intervention strata (PTCA and CABG) 
compared with the medical management stratum . Inter­
ventions have a major impact on the classification of 
angina pectoris. No additional benefit o f  pravastatin 
could be established in the intervention strata. After 2 
years of therapy, the results of the intervention strata 
were actually better than the medical m anagem ent stra­
tum. Nonscheduled interventions may cause a confound­
Pravastatin Placebo
Fig 1, Classification of angina pectoris according to the Cana­
dian Cardiovascular Society. In three patients in the placebo 
group and one patient in the pravastatin group, follow-up was 
not available.
change in exercise time (s)
Fig 2. Scatterplot with regression line of the re la tion  between 
the changes in HMTT and total exercise tim e. The inverse 
relation is significant.
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ing effect on the analysis of the classification of angina 
pectoris in the medical management group. For that 
reason, the classification of angina pectoris before the 
nonscheduled intervention was considered an end point. 
The periods of unstable angina were not included be­
cause they may represent acute plaque rupture and 
thrombosis rather than progression of fixed coronary 
artery atherosclerosis. Nevertheless, the clinical benefit 
of pravastatin treatment in the medical management 
stratum is evident.
Comparison With Other Studies
The number of studies evaluating lipid-lowering ther­
apy with assessment of myocardial perfusion is limit­
ed.24"28 Thallium-20'1 scintigraphy and PET were used 
for semiquantitative evaluation. In these studies, myo­
cardial perfusion defects improved in the actively 
treated patient groups, without significant changes in 
coronary anatomy, as measured or supposed. In the 
“long-term intense risk factor modification study,5' the 
change in dipyridamole PET images of normalized 
counts worsened in control subjects by 13.5% and im­
proved in the experimental group by 4.2%, numbers that 
correspond very well with our results.27 In some studies, 
patients in the active treatment group were subjected to 
a regular exercise program. The effect of training pre­
cludes a direct comparison of the effect of lipid-lowering 
therapy on the exercise parameters.25’26 In the short­
term lipid-lowering study with fluvastatin, the improve­
ment of perfusion defects is established after only 12 
weeks of therapy. The improvement was especially no­
ticeable in areas of ischemia.28 The positive effects of 
these studies on myocardial perfusion are not eluci­
dated. Suggested mechanisms are improved endotheii- 
um-dependent vasodilation, improved collateral circula­
tion, and changes in blood viscosity. The data of the 
effect of HMG-coenzyme A  reductase inhibitors on 
blood viscosity are conflicting.29-31 In studies with lova- 
statin and simvastatin, no effect on blood viscosity was 
observed, so it is unlikely that a change in blood viscosity 
caused the changes in myocardial perfusion. Coronary 
resistance vessels are spared from the development of 
overt atherosclerosis, but the endothelial function of the 
microcirculation can be disturbed in the presence of 
hypercholesterolemia,9 Thus, improved endothelial 
function remains the most likely explanation for the 
improvement in myocardial perfusion, which also may 
affect collateral circulation.
Study Limitations
Evaluation of exercise testing in the PTCA and CABG 
strata was influenced largely by the intervention, so we 
decided not to include these data in the effect analysis of 
pravastatin. Follow-up parameters were not available in 
several patients in the medical management stratum, 
mostly because of cardiovascular complications. These 
dropouts occurred predominantly in the placebo group 
and may have influenced the results of this study. 
However, these dropouts most likely caused underesti­
mation rather than overestimation of the difference in 
response between the pravastatin and placebo group.
Conclusions
In symptomatic men with coronary artery disease and 
normal to moderately raised cholesterol levels, pravasta­
tin therapy for 2 years resulted in a preserved regional 
myocardial perfusion, whereas this parameter deterio­
rated in patients on placebo. The group of patients on 
pravastatin had fewer clinical events and a trend toward 
preserved exercise capacity. The change in myocardial 
perfusion was better related with a change in exercise 
parameters than with a change in anatomic parameters. 
In lipid-lowering therapy, assessment of myocardial per­
fusion is advantageous because it represents a combined 
measure of the resistance to flow by the epicardial 
vessels and microcirculation. Functional evaluation of 
the coronary circulation deserves further investigation as 
a tool for evaluation of lipid-lowering therapy in patients 
with coronary artery disease because it might better 
reflect the clinical benefit for the patient.
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